131 related articles for article (PubMed ID: 19222832)
1. Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs.
Intile JL; Rassnick KM; Bailey DB; Al-Sarraf R; Chretin JD; Balkman CE; Flory AB; Kiselow MA; Wakshlag JJ
Vet Comp Oncol; 2009 Mar; 7(1):69-77. PubMed ID: 19222832
[TBL] [Abstract][Full Text] [Related]
2. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
Rassnick KM; Bailey DB; Malone EK; Flory AB; Kiselow MA; Intile JL
J Am Anim Hosp Assoc; 2014; 50(3):167-73. PubMed ID: 24659727
[TBL] [Abstract][Full Text] [Related]
4. Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
Treggiari E; Cossu G; Valenti P; Taylor A
Vet Comp Oncol; 2022 Sep; 20(3):577-586. PubMed ID: 35249267
[TBL] [Abstract][Full Text] [Related]
5. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Heading KL; Brockley LK; Bennett PF
Aust Vet J; 2011 Apr; 89(4):109-16. PubMed ID: 21418164
[TBL] [Abstract][Full Text] [Related]
6. The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: a pilot study.
Abrams-Ogg AC
Can J Vet Res; 2011 Jan; 75(1):73-6. PubMed ID: 21461200
[TBL] [Abstract][Full Text] [Related]
7. Autologous bone marrow grafts in dogs treated with lethal doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
Abb J; Netzel B; Rodt HV; Thierfelder S
Cancer Res; 1978 Jul; 38(7):2157-9. PubMed ID: 350384
[TBL] [Abstract][Full Text] [Related]
8. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE
J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992
[TBL] [Abstract][Full Text] [Related]
9. Methyl-CCNU: preclinical toxicologic evaluation of a single iv infusion in dogs and monkeys.
Schaeppi U; Fleischman RW; Phelan RS; Ethier MF; Luthra YK
Cancer Treat Rep; 1976 Oct; 60(10):1559-66. PubMed ID: 828519
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Smallwood K; Tanis JB; Grant IA; Blackwood L; Killick DR; Amores-Fuster I; Elliott J; Mas A; Harper A; Marrington M; Finotello R
Vet Comp Oncol; 2019 Jun; 17(2):165-173. PubMed ID: 30666777
[TBL] [Abstract][Full Text] [Related]
11. Treatment of canine mast cell tumors with CCNU (lomustine).
Rassnick KM; Moore AS; Williams LE; London CA; Kintzer PP; Engler SJ; Cotter SM
J Vet Intern Med; 1999; 13(6):601-5. PubMed ID: 10587263
[TBL] [Abstract][Full Text] [Related]
12. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
[TBL] [Abstract][Full Text] [Related]
13. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinicopathologic features, response to treatment, and risk factors associated with idiopathic neutropenia in dogs: 11 cases (1990-2002).
Brown CD; Parnell NK; Schulman RL; Brown CG; Glickman NW; Glickman L
J Am Vet Med Assoc; 2006 Jul; 229(1):87-91. PubMed ID: 16817719
[TBL] [Abstract][Full Text] [Related]
15. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.
Moore AS; London CA; Wood CA; Williams LE; Cotter SM; L'Heureux DA; Frimberger AE
J Vet Intern Med; 1999; 13(5):395-8. PubMed ID: 10499719
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs.
Kristal O; Rassnick KM; Gliatto JM; Northrup NC; Chretin JD; Morrison-Collister K; Cotter SM; Moore AS
J Vet Intern Med; 2004; 18(1):75-80. PubMed ID: 14765735
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects and outcome associated with dexamethasone administration in dogs with acute thoracolumbar intervertebral disk herniation: 161 cases (2000-2006).
Levine JM; Levine GJ; Boozer L; Schatzberg SJ; Platt SR; Kent M; Kerwin SC; Fosgate GT
J Am Vet Med Assoc; 2008 Feb; 232(3):411-7. PubMed ID: 18241109
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine)*.
Hosoya K; Lord LK; Lara-Garcia A; Kisseberth WC; London CA; Couto CG
Vet Comp Oncol; 2009 Dec; 7(4):244-55. PubMed ID: 19891695
[TBL] [Abstract][Full Text] [Related]
19. CCNU in the treatment of canine epitheliotropic lymphoma.
Williams LE; Rassnick KM; Power HT; Lana SE; Morrison-Collister KE; Hansen K; Johnson JL
J Vet Intern Med; 2006; 20(1):136-43. PubMed ID: 16496933
[TBL] [Abstract][Full Text] [Related]
20. Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors.
Hay JK; Larson VS
Can Vet J; 2019 Dec; 60(12):1326-1330. PubMed ID: 31814640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
